Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VZV-specific CD4+ T cell development after infection or Varivax vaccination in renal transplant recipients and healthy donors
2008-007235-40Phase 4Completed
- Sponsor
- Medical University of Innsbruck
- Start
- Mar 2009
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, Live Biotherapeutic Products → Microbiome Therapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of varicella virus vaccine live in chickenpox and Varicella zoster infection (3 arms), sponsored by Medical University of Innsbruck. Primary endpoints: VZV-specific CD4+ T cell kinetics and memory maintenance and Drop-out criteria for vaccination. Started Mar 2009; status: completed.
02
Drugs
varicella virus vaccine live
03
Conditions
chickenpoxVaricella zoster infection
Beyond the preview
Go deeper on 2008-007235-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007235-40.